<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057915</url>
  </required_header>
  <id_info>
    <org_study_id>4180</org_study_id>
    <secondary_id>5910</secondary_id>
    <secondary_id>4180</secondary_id>
    <nct_id>NCT00057915</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer</brief_title>
  <official_title>A Phase I Study of Active Immunotherapy With CAP-1 (6D) and CMVpp65 Peptide-Pulsed, Autologous Dendritic Cells Produced in the Aastromreplicell Cell Production System in Patients With Stage IV CEA Expressing Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's white blood cells mixed with peptides may make the&#xD;
      body build an immune response to kill cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in&#xD;
      treating patients with refractory stage IV cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and feasibility of administering 1 or 2 courses of vaccination with&#xD;
           carcinoembryonic antigen peptide 1-6D (CAP 1-6D)- and CMV pp65 peptide-pulsed autologous&#xD;
           dendritic cells in patients with refractory stage IV CEA-expressing malignancies.&#xD;
&#xD;
        -  Determine the ability of this regimen to induce CAP 1-6D- and CMV pp65-specific T cells&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine the antitumor effect of this regimen, in terms of progression-free survival,&#xD;
           of these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
      Patients undergo leukapheresis and collection of peripheral blood mononuclear cells from&#xD;
      which dendritic cells (DC) are generated and pulsed with carcinoembryonic antigen peptide&#xD;
      1-6D (CAP 1-6D) and CMV pp65 peptide. Patients are assigned to 1 of 2 vaccination cohorts.&#xD;
&#xD;
        -  Cohort I: Patients receive vaccination with CAP 1-6D-pulsed DC and CMV pp65&#xD;
           peptide-pulsed DC subcutaneously and intradermally every 3 weeks for a total of 4&#xD;
           vaccinations.&#xD;
&#xD;
        -  Cohort II: Patients receive vaccinations as in cohort I every 3 weeks for a total of 8&#xD;
           vaccinations.&#xD;
&#xD;
      For both cohorts, a safe dose of the vaccine is defined as the dose at which no more than 1&#xD;
      of 6 patients experiences unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients (6 per cohort) will be accrued for this study&#xD;
      within 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <description>The safety and feasibility of administering one cycle of CAP-1(6D) and CMV pp65 peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>12 weeks</time_frame>
    <description>The ability of the epitope pulsed DC to induce CAP-1(6D) and CMV pp65-specific T cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>CEA peptide 1-6D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CEA peptide 1-6D</intervention_name>
    <description>CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System</description>
    <arm_group_label>CEA peptide 1-6D</arm_group_label>
    <other_name>carcinoembryonic antigen peptide 1-6D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignancy that is refractory to standard therapy known to&#xD;
             have a survival benefit&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
          -  Carcinoembryonic antigen (CEA)-expressing tumor, as evidenced by 1 of the following:&#xD;
&#xD;
               -  Immunohistochemistry with at least 50% of the tumor with at least moderate&#xD;
                  intensity of staining&#xD;
&#xD;
               -  Peripheral blood CEA greater than 2.5 mg/dL&#xD;
&#xD;
               -  Tumor known to be universally CEA positive (i.e., colon or rectal cancer)&#xD;
&#xD;
          -  HLA-A201 positive&#xD;
&#xD;
          -  Measurable disease*&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion at least 20 mm by conventional&#xD;
                  techniques OR at least 10 mm by spiral CT scan NOTE: *Histologic or cytologic&#xD;
                  confirmation is not required for measurable disease restricted to a solitary&#xD;
                  lesion&#xD;
&#xD;
          -  Received at least 1 prior standard chemotherapy regimen known to have a survival&#xD;
             benefit&#xD;
&#xD;
          -  Previously resected brain metastases allowed provided CT scan or MRI was performed&#xD;
             within the past month and shows no metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL (transfusions or red blood cell growth factors [e.g.,&#xD;
             epoetin alfa] allowed)&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL (unless patient has Gilbert's disease)&#xD;
&#xD;
          -  SGOT/SGPT less than 1.5 times upper limit of normal&#xD;
&#xD;
          -  No hepatic disease that would preclude study participation&#xD;
&#xD;
          -  No viral hepatitis (including chronic hepatitis) by hepatitis B surface antigen and&#xD;
             hepatitis C serology&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2.5 mg/dL&#xD;
&#xD;
          -  No urinary tract infection&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No history of autoimmune disease, including any of the following:&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Ankylosing spondylitis&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
          -  No active acute or chronic infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other serious chronic or acute illness that would preclude study participation&#xD;
&#xD;
          -  No medical or psychological impediment that would preclude study compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer, controlled&#xD;
             carcinoma in situ of the cervix, or controlled superficial bladder cancer&#xD;
&#xD;
          -  No allergy to study vaccine components&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 6 weeks since prior steroid therapy (except steroids administered as&#xD;
             premedication for chemotherapy or contrast-enhanced studies)&#xD;
&#xD;
          -  Concurrent hormonal therapy allowed for patients with breast cancer&#xD;
&#xD;
          -  No concurrent steroid therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational therapy&#xD;
&#xD;
          -  At least 4 weeks since other prior therapy&#xD;
&#xD;
          -  Any number of prior therapies are allowed&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed for bone metastases&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy (e.g., azathioprine or cyclosporine)&#xD;
&#xD;
          -  No other concurrent experimental therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert K. Lyerly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Michael Morse, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

